Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Sankyo Writes Off Ranbaxy Buy

by Jean-François Tremblay
January 12, 2009 | A version of this story appeared in Volume 87, Issue 2

Japanese drugmaker Daiichi Sankyo will take a write-off of $3.85 billion following its acquisition of Ranbaxy Laboratories, one of India's leading manufacturers of generic pharmaceuticals. Sankyo announced its intention to buy most of Ranbaxy last summer. FDA subsequently banned many of the products Ranbaxy makes in India because of noncompliance with current Good Manufacturing Practices. However, Sankyo claims the hefty write-off is based on "unprecedented turmoil in equities markets." It still considers the acquisition an essential element of its strategy to become a major supplier of both innovative drugs and generics.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.